Ozempic Face: Why It Happens and What Helps
"Ozempic face" is everywhere: hollow cheeks, deeper folds, looser skin along the jaw, and a face that suddenly looks older or more tired than the person feels. The phrase makes it sound like a drug side effect. Mostly, it isn't.
"Ozempic face" is a media term, not a medical diagnosis. The published research points to a simpler explanation. Losing a meaningful amount of weight removes fat from the face as well as the body, and that loss sits on top of normal aging. A 2026 review in Aesthetic Surgery Journal notes that the name "can imply a drug-specific adverse effect, although similar changes occur after other forms of substantial weight loss."
This article explains what is actually happening, who tends to notice it most, and which treatments can help: hyaluronic acid fillers, biostimulators, and skin-quality treatments. It also covers the evidence gaps, because there are real ones.
Table of Contents
What "Ozempic face" actually means
Ozempic is a brand of semaglutide approved for type 2 diabetes. Wegovy, Zepbound and other incretin medications are used for chronic weight management. The nickname stuck to Ozempic because it was the name most people knew, not because that product does something unique to the face.
When clinicians describe the pattern, they list the same features again and again:
- Midface deflation. The cheeks look flatter, and the area under the eyes can look hollow.
- Temple hollowing. The sides of the forehead sink in.
- Deeper folds. Nasolabial folds (nose to mouth) and marionette lines (mouth to chin) look more pronounced.
- Laxity. Skin that was supported by fat now hangs a little, especially along the jawline and neck.
- Texture changes. Some people notice crepey or less elastic skin.
A 2025 systematic review of plastic-surgery literature found that GLP-1 receptor agonists are described as causing changes "resembling advanced aging." It also found that online searches for "Ozempic face" rose alongside searches for "face filler" and "plastic surgeons." Interest is clearly high. The quality of evidence is still modest. Most published work is reviews, surveys, case reports and small case series.
Is it the drug or the weight loss?
The best current answer: it is mostly the weight loss.
The face contains distinct fat compartments. Some sit just under the skin (superficial), and some sit deeper against the bone. In 2025, Vanderbilt facial plastic surgeons published what they called one of the first quantitative assessments of the phenomenon. They looked at 20 patients who had head and neck CT or MRI scans both before and after starting a GLP-1 medication. Average weight loss was 11 kg (about 24 lb). The median drop in total midfacial volume was 9%. Superficial fat fell more (11%) than deep fat (7%). Their regression estimated about 7% midfacial volume loss for every 10 kg of body weight lost.
That relationship to the amount of weight lost matters. It is what you would expect from fat loss in general, not a toxic effect of a specific drug. The 2026 Aesthetic Surgery Journal review, which screened 958 records and included 46 reports, reached the same conclusion: "current evidence favors weight-loss-associated deflation superimposed on baseline anatomy and aging." It also noted that post-bariatric surgery studies describe similar facial deflation and increased apparent age.
What is still unknown:
- Speed. Many clinicians suspect faster loss gives skin less time to adapt. The 2026 review says the independent effect of the rate of weight loss "remain[s] uncertain."
- Hormones. Whether menopause or hormone therapy changes the picture is also uncertain.
- Skin itself. A 2026 literature review describes dermal thinning and reduced elasticity with GLP-1 use, but it draws on mixed-quality studies, including case reports. It is not established that these medications damage skin directly.
The honest summary: if you lose a large amount of weight by any route (medication, surgery, or diet and exercise), your face may change. GLP-1 medications made large weight loss far more common, so more people are noticing it.
Who is more likely to notice it
Not everyone who loses weight on a GLP-1 medication dislikes how their face looks. Many people like the result. The changes tend to be more noticeable with:
- Larger total weight loss. The imaging data tie facial volume loss to kilograms lost.
- Older age. Skin elasticity and bone support decline with age. A classic study of 186 pairs of identical twins found that the twin with a higher BMI looked older when younger, but younger after about age 40 (for a 4-point BMI difference) or 55 (for an 8-point difference). Facial fat helps hide age later in life.
- A naturally lean or angular face. There is less reserve to lose.
- Sun damage and smoking history. Both were linked to an older appearance in the same twin study.
What can help, layer by layer
Think of the face in layers: bone, deep fat, superficial fat, and skin. A good plan matches the treatment to the layer that changed. One product rarely fixes everything.
| Concern | Options a provider may discuss | What to know |
|---|---|---|
| Lost volume (cheeks, temples, under-eye area) | Hyaluronic acid (HA) fillers | Immediate, reversible with an enzyme; temporary |
| Gradual support and skin firmness | Biostimulators (Sculptra, Radiesse) | Builds over weeks to months; usually a series of sessions |
| Texture, fine lines, crepey skin | Skin resurfacing (e.g., Alma Opus plasma), microneedling | Treats the skin surface, not lost volume |
| Significant sagging or excess skin | Surgical consultation | Injectables and devices cannot remove large amounts of skin |
Hyaluronic acid fillers
HA fillers replace volume directly. They can restore cheek support, soften temple hollows, and reduce the shadow of deep folds. Results are visible right away. They are temporary, and HA can be dissolved with an enzyme if needed. In a 2026 survey of 406 aesthetic clinicians who treat patients after GLP-1 weight loss, respondents rated HA the best treatment for facial concerns for an average of 47% of their patients. That reflects practice patterns, not proof that HA is superior.
The most serious filler risk is accidental injection into a blood vessel. The FDA warns this can cause tissue death, vision problems including blindness, and stroke. It is rare, but it is why anatomy training and an experienced injector matter. For more on how fillers and neuromodulators differ, see our guide to Botox and dermal fillers.
Biostimulators: Sculptra and Radiesse
Biostimulators work differently. Instead of filling a space, they prompt your body to make its own collagen over time. Our injectable team offers biostimulators, including Sculptra (poly-L-lactic acid) and Radiesse (calcium hydroxylapatite), where appropriate.
- Sculptra builds gradually. The manufacturer describes a typical course of about three sessions spaced at least three to four weeks apart.
- Radiesse provides structural support plus collagen stimulation. It can also be diluted ("hyperdilute"), which is the approach used in the small GLP-1 study below.
The GLP-1-specific evidence is early. A 2025 case series followed four patients on GLP-1 medications who received hyperdilute Radiesse in the lower face. They lost an average of about 9% of body weight, yet their measured facial volume stayed stable or improved at six months. Four patients is a signal, not proof. It does support the idea that biostimulators may help preserve support during weight loss, which is why some clinicians start them before the weight has fully come off.
Skin quality: resurfacing and Alma Opus
Fillers and biostimulators address volume and support. They do not fix rough texture, fine lines or crepey skin. That is the job of skin-quality treatments.
Rejuv offers Alma Opus plasma resurfacing, a fractional plasma treatment (not a laser) that a provider may consider for texture, fine lines and overall skin quality. Microneedling and other options on our advanced skin treatments page may also fit. Be skeptical of any promise that a device will "tighten" significant sagging. Devices can improve the skin surface. They do not replace lost volume, and they cannot remove meaningful excess skin. Our article on skin tightening and body contouring after weight loss covers the limits in more detail.
Neuromodulators
Botox and similar products relax muscles that cause expression lines. They do not restore volume, so on their own they will not fix a deflated face. They can be a useful add-on for forehead lines, frown lines or a downturned mouth.
When surgery is the honest answer
If loose skin along the jaw and neck is the main issue, a facelift or neck lift consultation may be more realistic than injectables. A good injector will tell you when you have reached the limits of what needles and devices can do.
Timing: should you wait until your weight is stable?
This is one of the most common questions, and there is no single rule.
The case for waiting: If you are still losing weight, filler placed today may look different in three months as more fat disappears. Your provider can also judge your final anatomy better once things settle.
The case for starting earlier: Collagen-stimulating treatments take months to build. Some clinicians begin biostimulators or skin-quality treatments during weight loss to support the tissue as it changes. A 2026 Clinics in Dermatology review recommends a "health-first approach that prioritizes tissue preservation" and planning the sequence of treatments across the weight-loss journey.
A reasonable middle path for many people: focus on skin quality and gradual biostimulation while weight is still changing, then add or fine-tune HA filler once your weight has been stable for a while. Your provider should explain why a specific timeline fits you.
Protect the foundation first
Some of the best "Ozempic face" prevention has nothing to do with injections.
- Protect lean mass. The Clinics in Dermatology review lists muscle loss (sarcopenia) alongside fat loss and bone changes as contributors to facial change. Adequate protein and resistance training help preserve muscle. See muscle preservation during weight loss and protein during GLP-1 treatment.
- Do not chase the fastest possible loss. Whether speed independently worsens facial changes is unproven. Still, dose and pace decisions belong with your prescriber, not a social-media timeline. Do not change your medication on your own.
- Protect your skin. Daily sunscreen and not smoking were linked to a younger appearance in the twin data, and both are good for skin regardless.
If you are on a GLP-1 medication through our medical weight management program, tell your provider if facial changes bother you. That conversation can shape both your weight plan and any aesthetic plan.
Questions to ask before treatment
- Which layer is the problem: volume, support, skin quality, or excess skin?
- Is my weight stable enough for filler, or should we start with something gradual?
- Which product are you proposing, and is it FDA-approved for this area?
- How many sessions are typical, and when would I expect to see change?
- What are the risks, including vascular complications, and how would you handle one?
- What will this treatment not do for me?
Frequently asked questions
Is "Ozempic face" a real medical condition?
It is a real pattern of change, but not a formal diagnosis. Current evidence points to facial fat loss from substantial weight loss, layered on normal aging, rather than a drug-specific side effect. Similar changes are described after bariatric surgery.
Does Ozempic face go away?
Lost facial fat does not usually return unless weight is regained. Skin quality can improve with time and care, and volume can be restored with treatment. If you stop a medication and regain weight, some fullness may return, but that is not a reason to stop. Discuss any medication change with your prescriber.
Fillers vs. Sculptra: which is better for Ozempic face?
They do different jobs. HA fillers restore volume immediately and can be dissolved. Sculptra and other biostimulators build collagen gradually over a series of sessions. Many plans combine them. Which fits you depends on your anatomy, timing, budget and goals.
Can I get filler while I'm still on a GLP-1 medication?
Often, yes. Being on the medication is not by itself a reason to avoid treatment. The bigger question is whether your weight is still changing. Tell your injector about all your medications and your weight-loss timeline.
Will skin tightening fix a sagging jawline?
Energy-based treatments can improve skin texture and quality. They cannot replace lost volume or remove significant excess skin. For marked sagging, a surgical consultation may be the more honest recommendation.
The bottom line
"Ozempic face" is a catchy name for something ordinary: when you lose a lot of weight, your face loses fat too, and that can make age more visible. The research so far blames the weight loss, not a unique toxicity of one drug, and it ties the amount of facial volume lost to the amount of weight lost.
That is good news in one way. It means the problem is understandable and, for many people, treatable. HA fillers can restore volume. Biostimulators like Sculptra and Radiesse can rebuild support gradually. Skin-quality treatments like Alma Opus address texture. Protein, strength training and sun protection help protect the foundation. The evidence for treatments in this specific group is still early, so a careful plan, built around your anatomy and timeline, matters more than any single product. No treatment can guarantee a specific result.
Related reading: Fake Botox & Unlicensed Injectors: Red Flags · Microdosing GLP-1s: Trend vs. Evidence · Wegovy Pill vs Foundayo: GLP-1 Pills Compared
Sources
- Yoo KH. Glucagon-Like Peptide-1 Receptor Agonist-Associated Facial Changes: A Comprehensive Review of Pathophysiology, Clinical Manifestations, Risk Factors, Prevention, and Management. Aesthetic Surgery Journal. 2026 (online ahead of print). doi:10.1093/asj/sjag230
- Sharma RK, Vittetoe KL, Barna AJ, et al. Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists. Otolaryngology–Head and Neck Surgery. 2025;173(2):360-366. doi:10.1002/ohn.1209
- Daneshgaran G, Shauly O, Gould DJ. "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. Aesthetic Surgery Journal Open Forum. 2025;7:ojaf056. doi:10.1093/asjof/ojaf056
- Fathizadeh S, Hwang AS, Hoss E. "Ozempic Face" and Facial Aging. Clinics in Dermatology. 2026 (online ahead of print). doi:10.1016/j.clindermatol.2026.10.004
- Guyuron B, Rowe DJ, Weinfeld AB, et al. Factors contributing to the facial aging of identical twins. Plastic and Reconstructive Surgery. 2009;123(4):1321-1331. doi:10.1097/PRS.0b013e31819c4d42
- Durairaj KK, McCarthy AD, Yambao M, Linnemann-Heath J. Hyperdilute Radiesse Preserves Facial Volume in Glucagon-Like Peptide-1 Receptor Agonist Users Undergoing Rapid Weight Loss. Aesthetic Surgery Journal Open Forum. 2025;7:ojaf088. doi:10.1093/asjof/ojaf088
- Fabi S, Yoo J, Kaufman-Janette J, et al. Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss. Dermatologic Surgery. 2026;52(6S):S23-S28. doi:10.1097/DSS.0000000000005166
- Barone M, Brunetti B, D'Emilio R, et al. Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review. Aesthetic Plastic Surgery. 2026;50(13):5403-5407. doi:10.1007/s00266-026-05820-4
- Dermal Fillers (Soft Tissue Fillers) (U.S. Food and Drug Administration)
- Sculptra frequently asked questions (Galderma)
This article is provided for general educational purposes and is not a substitute for individualized medical advice, diagnosis, or treatment. Aesthetic and weight-management decisions, including any change to a prescription medication, should be made with a licensed provider who knows your health history and goals.